Cite
Murai K, Ureshino H, Kumagai T, et al. Low-dose dasatinib in older patients with chronic myeloid leukaemia in chronic phase (DAVLEC): a single-arm, multicentre, phase 2 trial. Lancet Haematol. 2021;8(12):e902-e911doi: 10.1016/S2352-3026(21)00333-1.
Murai, K., Ureshino, H., Kumagai, T., Tanaka, H., Nishiwaki, K., Wakita, S., Inokuchi, K., Fukushima, T., Yoshida, C., Uoshima, N., Kiguchi, T., Mita, M., Aoki, J., Kimura, S., Karimata, K., Usuki, K., Shimono, J., Chinen, Y., Kuroda, J., Matsuda, Y., Nakao, K., Ono, T., Fujimaki, K., Shibayama, H., Mizumoto, C., Takeoka, T., Io, K., Kondo, T., Miura, M., Minami, Y., Ikezoe, T., Imagawa, J., Takamori, A., Kawaguchi, A., Sakamoto, J., & Kimura, S. (2021). Low-dose dasatinib in older patients with chronic myeloid leukaemia in chronic phase (DAVLEC): a single-arm, multicentre, phase 2 trial. The Lancet. Haematology, 8(12), e902-e911. https://doi.org/10.1016/S2352-3026(21)00333-1
Murai, Kazunori, et al. "Low-dose dasatinib in older patients with chronic myeloid leukaemia in chronic phase (DAVLEC): a single-arm, multicentre, phase 2 trial." The Lancet. Haematology vol. 8,12 (2021): e902-e911. doi: https://doi.org/10.1016/S2352-3026(21)00333-1
Murai K, Ureshino H, Kumagai T, Tanaka H, Nishiwaki K, Wakita S, Inokuchi K, Fukushima T, Yoshida C, Uoshima N, Kiguchi T, Mita M, Aoki J, Kimura S, Karimata K, Usuki K, Shimono J, Chinen Y, Kuroda J, Matsuda Y, Nakao K, Ono T, Fujimaki K, Shibayama H, Mizumoto C, Takeoka T, Io K, Kondo T, Miura M, Minami Y, Ikezoe T, Imagawa J, Takamori A, Kawaguchi A, Sakamoto J, Kimura S. Low-dose dasatinib in older patients with chronic myeloid leukaemia in chronic phase (DAVLEC): a single-arm, multicentre, phase 2 trial. Lancet Haematol. 2021 Dec;8(12):e902-e911. doi: 10.1016/S2352-3026(21)00333-1. PMID: 34826413.
Copy
Download .nbib